Jacob Appelbaum

@sanamloghavi Post your pre-print (or link once accepted)! @sanamloghavi , wouldn’t you agree that megakaryocyte morphology is an important consideration for differentiating ET v pre-fibrotic MF? I view risks/Rx of these diseases differently. Nice example of what we should look for!

Proofing 📜 Seeing🔬📸U took frm a real life case in a paper is uniquely rewarding Imagine if the pt who's cells we📸could see their cell(s) made it to a paper & is teaching something, Wudn’t that be😍? A pt(artist) once requested pic of her leukemia frm me & wanted 2 frame it❤

@SCTherapeutics @2seventybio @GoHealio More options for patients with AML are desperately needed. This is an important proof of concept that a drug can be used to active a controllable CART cell therapy in patients.

Early results from our PLAT-08 clinical trial in collaboration with @2seventybio showed activity against acute myeloid leukemia blasts in one patient. "This opens a new era in CAR T-cell therapy,” Dr. Jacob Appelbaum tells @GoHealio. tinyurl.com/2d64dnz3 #AML #ASGCT2023